RxDoctor Payments Data

Panupong Jiamsripong, MD

Cardiovascular Disease · Aiea, HINPI 1801186200

Payments from drug & device makers

What this record shows

13 manufacturers reported payments, led by Medtronic at 43.6% of the total. Reporting peaked in 2019 at $2,480 and has fallen 89.8% since, to $253 in 2025.

$4,710in general payments, 2019–2025

Across 31 payments — averaging $151.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Penumbra, Inc.$987
  • Abbott$440
  • Boston Scientific$263
  • Akcea Therapeutics, Inc.$152
  • Johnson & Johnson$150
  • plus $662 from 7 others

What the payments were for

  • Travel & lodging$2,33650%
  • Food & beverage$2,37450%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,710 in reported general payments places this provider in the 70th percentile of 73 cardiovascular disease providers in Hawaii.

See all cardiovascular disease providers in Hawaii

Medicare billing

Part B allowed, 2024
$93,212
Medicare patients
679
Services billed
1,598

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban110$168,887
EntrestoSacubitril/Valsartan56$97,272
JardianceEmpagliflozin28$39,787
XareltoRivaroxaban38$38,303
Repatha SureclickEvolocumab32$28,691
VascepaIcosapent Ethyl25$9,739
Metoprolol Succinate273$4,925
Atorvastatin Calcium177$4,627
Ezetimibe30$1,922
Losartan Potassium100$1,241
Rosuvastatin Calcium30$1,212
Carvedilol91$1,145
Amlodipine Besylate115$1,033
ClopidogrelClopidogrel Bisulfate40$1,009
Diltiazem 24hr Er (Cd)Diltiazem Hcl20$577

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$71$97,27256 claims
Johnson & JohnsonXarelto$150$38,30338 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 73 cardiovascular disease providers in Hawaii.

Other cardiovascular disease in Aiea

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →